Fidelity Investments
PHAT icon

Fidelity Investments’s Phathom Pharmaceuticals PHAT Stock Holding History

Fidelity Investments’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.3K Buy
8,230
+1,205
+17% +$13.7K ﹤0.01% 4024
2026
Q1 		$78K Sell
7,025
-156
-2% -$1.97K ﹤0.01% 3905
2025
Q4 		$119K Buy
7,181
+182
+3% +$2.6K ﹤0.01% 3669
2025
Q3 		$82.4K Buy
6,999
+1,118
+19% +$11.5K ﹤0.01% 3745
2025
Q2 		$56.4K Sell
5,881
-503,701
-99% -$2.79M ﹤0.01% 3843
2025
Q1 		$3.2M Sell
509,582
-291,819
-36% -$1.77M ﹤0.01% 2302
2024
Q4 		$6.51M Sell
801,401
-502,713
-39% -$6.23M ﹤0.01% 2072
2024
Q3 		$23.6M Buy
1,304,114
+1,301,458
+49,001% +$18.2M ﹤0.01% 1652
2024
Q2 		$27.4K Buy
2,656
+572
+27% +$5.89K ﹤0.01% 3924
2024
Q1 		$22.1K Sell
2,084
-1,249
-37% -$10.6K ﹤0.01% 3973
2023
Q4 		$30.4K Buy
3,333
+1,444
+76% +$12.4K ﹤0.01% 3747
2023
Q3 		$19.6K Sell
1,889
-35,435
-95% -$486K ﹤0.01% 3816
2023
Q2 		$534K Buy
37,324
+36,556
+4,760% +$421K ﹤0.01% 2633
2023
Q1 		$5.48K Buy
768
+73
+11% +$641 ﹤0.01% 4362
2022
Q4 		$7.8K Sell
695
-520
-43% -$5.36K ﹤0.01% 4104
2022
Q3 		$13K Buy
1,215
+837
+221% +$7.97K ﹤0.01% 3993
2022
Q2 		$3K Sell
378
-105
-22% -$1.08K ﹤0.01% 4482
2022
Q1 		$7K Buy
+483
New +$7.8K ﹤0.01% 4346
2021
Q4 		– Sell
-154,200
Closed -$4.95M – 4797
2021
Q3 		$4.95M Buy
+154,200
New +$5.12M ﹤0.01% 2372

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments's PHAT Position: Q2 2026 in Review

Fidelity Investments increased its Phathom Pharmaceuticals (PHAT) stake by 17% in Q2 2026, buying an estimated $13.7K and bringing the position to 8,230 shares worth $89.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4024.

Fidelity Investments first reported a position in PHAT in Q3 2021 and has held it in 19 quarters since. The position peaked at $23.6M in Q3 2024. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Fidelity Investments held 8,230 shares of Phathom Pharmaceuticals worth $89.3K as of Q2 2026.
  • Fidelity Investments bought 1,205 Phathom Pharmaceuticals shares in Q2 2026, an estimated $13.7K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4024 holding.
  • Fidelity Investments first reported a position in Phathom Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Fidelity Investments's Phathom Pharmaceuticals position peaked at $23.6M in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.